BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 12
• 13
• 14
• 15
• 16
• 18
• 19
• 20
• 21
• 22
• 23

• Press Releases

  CHMP recommends approval of Johnson & Johnson’s TALVEY®▼ (talquetamab) plus daratumumab in earlier line treatment of relapsed/refractory multiple myeloma

  October 16, 2026

   · 

  18 min read
• Press Releases

  Semax Peptide Introduced by Kylo Peptides for Laboratory Use

  October 16, 2026

   · 

  7 min read
• Press Releases

  Estuary Biotherapeutics Launches with $103 Million to Develop Targeted Gene Therapies for Kidney Disease

  October 16, 2026

   · 

  9 min read
• Press Releases

  TRYNGOLZA® (olezarsen) recommended for approval in the EU by CHMP for severe hypertriglyceridemia (sHTG)

  October 16, 2026

   · 

  9 min read
• 

  Funding

  OrbiMed raises two new life sciences funds worth $3B with one aiming for Asia

  The sixth cycle of OrbiMed’s Asia Partners fund included one with more than $1 billion earmarked for life science companies based on the Eastern continent.

  October 16, 2026

   · 

  1 min read

   · 

  Tristan Manalac
• Press Releases

  Tango Therapeutics to Present Updated Vopimetostat + RAS(ON) Combination Data at European Society For Medical Oncology (ESMO) Congress 2026

  October 16, 2026

   · 

  3 min read
• Press Releases

  OXB Appoints Joachim Kreuzburg as Independent Non-Executive Director

  October 16, 2026

   · 

  3 min read
• Press Releases

  Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Updated Dosing Regimen Across All Approved Cancer Types

  October 16, 2026

   · 

  18 min read
• Press Releases

  Fractyl Health’s Revita Meets Six-Month Co-Primary Endpoint in Ongoing REMAIN-1 Pivotal Study, With Highly Statistically Significant Reduction in Weight Regain After GLP-1 Discontinuation

  October 16, 2026

   · 

  11 min read
• Press Releases

  Adial Pharmaceuticals Appoints David Rubenstein, M.D., Ph.D., as Chief Scientist to Advance its Colon-Targeted AhR Agonist, AT177, for Ulcerative Colitis

  October 16, 2026

   · 

  5 min read